Penumbra Inc (PEN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.

Total Revenue Chart for Penumbra Inc

Penumbra Inc (PEN) revenue for FY2025 was USD 1.4B, a 17.5% change from FY2024. Penumbra Inc's revenue grew from USD 73.1M in 2012 to USD 1.4B in 2025 (1819.1% over 13 years). Earnings per share grew from USD 0.17 in 2013 to USD 4.52 in 2025 (2604.2%). Revenue compound annual growth rate: 5-year CAGR of 20.2%, 10-year CAGR of 22.4%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$12.49B
Implied Share Price
$317.05
Enterprise Value
$12.14B
Revenue (TTM)
$1.50B
EBITDA
$204.28M
Profit Margin
10.67%
Trailing P/E
77.90
Forward P/E
55.56
Price/Book (MRQ)
8.22
Price/Sales (TTM)
8.30
EV/EBITDA
54.60
EV/Revenue
8.06
Dividend Yield
—
Book Value
$38.86
Free Cash Flow (FY2025)
$174.93M
Free Cash Flow Yield
1.40%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.